Day: July 6, 2021

Posted on

CoImmune, Inc. Appoints Michael Fekete and Greg Tibbitts to its Board of Directors

DURHAM, N.C., July 06, 2021 (GLOBE NEWSWIRE) — CoImmune, Inc., a clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class yet more affordable cellular immunotherapies, today announced the appointments of Michael Fekete and Greg Tibbitts, to the Company’s board of directors. Mr. Fekete and Mr. Tibbitts bring with them a wealth of financial, capital markets and strategic expertise, and prior board level experience.

Mr. Fekete is an advisor and board member for companies in the pharmaceutical, biotechnology and medical device industries. His areas of expertise include business strategy, capital markets, M&A and corporate governance developed through 35 years as an investment banker, independent advisor and board member for U.S. and international public and private companies. He currently serves as a member for SeaSpine, Inc. (NASDAQ: SPNE), a California based medical technology company focused on surgical solutions for the treatment of spinal disorders, and DFB Pharmaceuticals, a Texas based, private investment and development company focused on the formation and building of businesses in the pharmaceutical industry. He previously worked as an investment banker for Wells Fargo/Wachovia Securities, CIBC World Markets, Oppenheimer & Co., and L.F. Rothschild, Unterberg, Towbin. He obtained his B.S. in Finance from The Pennsylvania State University.

Mr. Greg Tibbitts is a Certified Public Accountant and has over 30 years of experience as a financial executive and a public accountant. His expertise includes addressing technical accounting issues, multiple public and private equity financings, complex operations, and direct interactions with the SEC on IPO and secondary offerings. He has worked as a Chief Financial Officer for both public and private companies and now operates a business advisory firm. He served as a board member for IDMI Pharma, Inc., a NASDAQ listed biotech company prior to its acquisition. He obtained a B.B.A. in Accounting at University of San Diego and a M.B.A. at San Diego State University.

“We are excited to welcome Mike and Greg to the CoImmune board,” stated Dr. Charles Nicolette, chief executive officer and member of the board of directors. “These gentlemen bring considerable biotechnology industry and strategic expertise that will benefit CoImmune as we seek to advance our novel pipeline of cell-based immunotherapies directed at important diseases, including acute lymphoblastic leukemia and advanced renal cell carcinoma.”

About CoImmune, Inc.
CoImmune is a privately held, clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class yet more affordable cellular immunotherapies. Our allogeneic CAR-CIK technology platform for liquid and solid tumors is a variation on CAR-T therapy that promises enhanced efficacy with greatly reduced toxicity. Our autologous RNA-loaded dendritic cell technology for solid tumors uses amplified total tumor mRNA to program highly engineered dendritic cells to generate immune responses against neoantigens without the need to identify them.

For more information, visit www.coimmune.com.

Contact:
Lori Harrelson
Chief Financial Officer
lharrelson@coimmune.com
919-287-6349

Posted on

TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule

58 Clinical Trial Sites, 11 Countries

EDMONTON, Alberta, July 06, 2021 (GLOBE NEWSWIRE) — Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment completion in coopERA Breast Cancer (WO42133/TRIO038), a Phase 2 randomized, multi-center, open-label clinical trial of giredestrant (GDC-9545) sponsored by F. Hoffmann-La Roche. This comes shortly after completion of the planned study interim analysis provided encouraging results and supported continuation of the study.

Giredestrant is an oral selective estrogen receptor degrader (SERD) that was shown to be well tolerated with encouraging tumour activity both alone and in combination with palbociclib in estrogen-receptor positive (ER+) metastatic breast cancer patients.

The trial is investigating the ability to expand the safety and efficacy of giredestrant as monotherapy and in combination with palbociclib into the early breast cancer setting. Enrolment of 221 patients was completed three months ahead of schedule. The trial design evaluates the efficacy, safety, and pharmacokinetics of presurgical treatment with giredestrant plus palbociclib compared with anastrozole plus palbociclib for postmenopausal women with ER+ and HER2-negative untreated early breast cancer.

“To have patient enrolment completed three months ahead of schedule, despite the global pandemic, reinforces the strength of commitment of TRIO’s investigator network,” stated Dr. Vanesa Quiroga, a member of the trial’s Steering Committee, GEICAM and Catalan Institute of Oncology. “The scale of interest from patients further underlines the urgency to bring forward new treatment options to treat early stage breast cancer.”

More information on the coopERA Breast Cancer trial (WO42133/TRIO038/coopERA) can be found at clinicaltrials.gov (NCT04436744).

About TRIO
TRIO advances translational cancer research by introducing innovative and novel targeted therapeutic concepts into the clinical trial setting. With international offices in Edmonton (Canada), Paris (France), Montevideo (Uruguay), TRIO’s global reach is expansive. Our goal as an academic clinical research organization is to find the shortest path to saving lives. Additional information on TRIO can be found by visiting https://www.trioncology.org. Interested parties may also follow TRIO on Twitter (twitter.com/TRIOncology).

TRIO Media Inquiries:
Launa Aspeslet, PhD
CEO, TRIO
Email: launa.aspeslet@trioncology.org
Phone: 780-702-2260

Posted on

Cambodia’s Education for Sustainable Development 2030

The Ministry of Education, Youth and Sports in collaboration with UNESCO has organised a consultation workshop on Education for Sustainable Development 2030 in Cambodia.
The meeting took place yesterday through a video conference under the presidency of H.E. Hang Chuon Naron, Minister of Education, Youth and Sports and Mr. Sardar Umar Alam, UNESCO Representative to Cambodia.
Some 200 education senior officials, education policy makers at different levels, experts, UNESCO representatives, and concerned partners joined the virtual meeting.
The meeting aimed at promoting a participatory preparation of five education priorities to support sustainable development 2030.
The five priorities include prioritisation policies, positive change for learning, building education capacity, youth’s empowerment and movement, and acceleration of local activities.

Source: Agency Kampuchea Press

Posted on

Cambodia Prepares for Asian Hockey Championship in Thailand

Cambodian Hockey Federation (CHF) will send female hockey athlete team to attend the Asian Hockey Championship to be held in November in Thailand.
The update was shared on July 5 by its federation’s Secretary General Mr. Kaing Sothea, adding that the event will further improve technical quality of Cambodian athletes for the 2023 SEA Games hosted by Cambodia.
The Asian Hockey Championship is expected to attract participation of female hockey athletes from 30 member countries of Asian Hokey Federation, he added.
Cambodia will include hockey sport to the upcoming 32nd SEA Games, and the Ministry of Education, Youth and Sports, National Olympic Committee of Cambodia (NOCC), and Cambodian SEA Games Organising Committee (CAMSOC) are pushing it as a potential sport for the 32nd SEA Games hosted by Cambodia in 2023.

Source: Agency Kampuchea Press

Posted on

OECD-FAO Outlook Sees Big Rice Exporters Losing Market Share to Cambodia and Myanmar

Cambodian rice exporters are likely to benefit as the market share of top exporters India, Thailand, Viet Nam, Pakistan and the United States declines over the next 10 years.
The projection appears in the annual agricultural outlook by the Organisation for Economic Cooperation and Development (OECD) — a club of rich countries — and the Food and Agriculture Organisation of the United Nations (FAO).
Released in Paris and Rome on Monday, the 10-year outlook projected world trade in cereals — including wheat, maize and rice — to rise by 21 percent to 542 million tonnes by 2030.
“India, Viet Nam and Thailand will continue to lead global rice trade, but Cambodia and Myanmar are expected to play an increasingly important role in global rice exports,” it said.
Over the past 10 years, the outlook said, international rice trade grew at an average rate of 1.5 percent a year.
Growth in rice trade is expected to accelerate to about 2.6 percent a year over the coming decade with exports rising by 16 million tonnes to 62 million tonnes by 2030.
“The export share of the top five major rice exporters – India, Thailand, Viet Nam, Pakistan, and the United States – is expected to fall from 74 percent to 70 percent,” the outlook said.
Changes in varieties and increased focus on cultivating higher quality strains “will certainly help Viet Nam to reduce its dependence on China,” it added.
At the same time, “Thailand is projected to continue playing an important export role, but is expected to face more competition.”
“The group of the five largest exporters will lose market shares to countries in the less developed countries (LDC) in Asia, particularly Cambodia and Myanmar, as these countries become more competitive internationally.”
The outlook expects rice shipments from less developed Asian countries to more than double from 4 million tonnes to 10 million tonnes by 2030.
“Large exportable supplies will allow these countries to capture a greater share of Asian and African markets.”
The outlook noted that the Indica rice variety historically accounted for most rice traded internationally.
“However, demand for other varieties is expected to continue to grow over the next ten years,” it said.
The other major type of rice traded internationally is the Japonica variety.
“Despite their different market structures in terms of production zones, consumer preferences and policies, most agricultural models do not distinguish between the two varieties,” the outlook said.
In the medium and long term, however, climate change is expected to affect production of both varieties.
Projections using a new Rice Economy Climate Change model showed that international Japonica rice prices would be “more volatile” than those for Indica rice.
Modeling also looked at the impact of agricultural investments on Indica and Japonica rice markets, including price stability, based on six scenarios for climate change over the mid to long-term.
Under two scenarios, modeling found that knowledge and innovation systems in Viet Nam and China “will play a significant role in stabilising international Indica and Japonica rice prices … in the mid-to long-term, as rice production is increasingly affected by climate change.”
The model included Indica and Japonica markets in Thailand, Viet Nam, Indonesia, Malaysia, the Philippines, Cambodia, Laos, Myanmar, China, Japan, Korea, India, United States, the European Union (including the United Kingdom), Bangladesh, Sri Lanka, Nepal, Pakistan, Brazil, Côte d’Ivoire, Egypt, Madagascar and Nigeria.

Source: Agency Kampuchea Press

Proudly powered by WordPress